Cannabinoids in Parkinson's Therapy

Parkinson's disease affects over 10 million people worldwide, with limited options for slowing its progression. Current treatments manage symptoms but do not address the underlying neurodegeneration.

The Question

Can cannabinoid compounds — particularly CBD and select minor cannabinoids — provide neuroprotective effects in the dopaminergic neurons most affected by Parkinson's? And can they meaningfully reduce motor symptoms in a way that complements existing therapies?

What We're Doing

We're reviewing the existing literature on cannabinoid receptor signaling in the basal ganglia, mapping the mechanisms by which CB1 and CB2 receptors interact with neuroinflammatory pathways, and identifying the most promising compounds for further investigation.

This is an early-stage research initiative. We are currently in the literature synthesis and hypothesis formation phase.

Why This Matters

Parkinson's research is underfunded relative to its disease burden. The endocannabinoid system represents a relatively unexplored therapeutic axis — one that could yield meaningful results if pursued rigorously.

Status

Active — literature review phase.